MA40074A - Composés liant ras multivalents - Google Patents

Composés liant ras multivalents

Info

Publication number
MA40074A
MA40074A MA040074A MA40074A MA40074A MA 40074 A MA40074 A MA 40074A MA 040074 A MA040074 A MA 040074A MA 40074 A MA40074 A MA 40074A MA 40074 A MA40074 A MA 40074A
Authority
MA
Morocco
Prior art keywords
methods
compounds
multivalent
binding compounds
compositions
Prior art date
Application number
MA040074A
Other languages
English (en)
Inventor
Brent R Stockwell
Matthew Welsch
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MA40074A publication Critical patent/MA40074A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne, entre autres, des composés qui lient sélectivement une protéine ras en deux sites ou davantage et des procédés pour leur synthèse. L'invention concerne également des compositions et des kits contenant les composés, ainsi que des procédés d'utilisation des composés et des compositions pour améliorer ou traiter les effets d'une maladie associée à une signalisation ras modifiée, comme un cancer, chez un sujet et des procédés pour provoquer la mort des cellules cancéreuses. L'invention concerne également des procédés d'identification d'un composé multivalent qui se lie sélectivement à une protéine cible.
MA040074A 2014-05-30 2015-05-29 Composés liant ras multivalents MA40074A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462005831P 2014-05-30 2014-05-30

Publications (1)

Publication Number Publication Date
MA40074A true MA40074A (fr) 2015-12-03

Family

ID=54700076

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040074A MA40074A (fr) 2014-05-30 2015-05-29 Composés liant ras multivalents

Country Status (5)

Country Link
US (1) US9926293B2 (fr)
EP (1) EP3148981A4 (fr)
CA (1) CA2950581A1 (fr)
MA (1) MA40074A (fr)
WO (1) WO2015184349A2 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
US9745319B2 (en) 2013-03-15 2017-08-29 Araxes Pharma Llc Irreversible covalent inhibitors of the GTPase K-Ras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
WO2016049568A1 (fr) 2014-09-25 2016-03-31 Araxes Pharma Llc Méthodes et compositions permettant l'inhibition de la ras
JP2017528498A (ja) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
ES2898765T3 (es) 2015-04-10 2022-03-08 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos
US10428064B2 (en) 2015-04-15 2019-10-01 Araxes Pharma Llc Fused-tricyclic inhibitors of KRAS and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058902A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
WO2017058728A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
EP3356351A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
EP3356359B1 (fr) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
EP3356347A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines kras portant la mutation g12c
EP3356349A1 (fr) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibiteurs de protéines mutantes kras g12c
WO2017058805A1 (fr) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibiteurs de protéines kras portant la mutation g12c
WO2017070256A2 (fr) 2015-10-19 2017-04-27 Araxes Pharma Llc Méthode de criblage d'inhibiteurs de ras
KR20180081596A (ko) 2015-11-16 2018-07-16 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (fr) 2016-03-30 2017-10-05 Araxes Pharma Llc Composés quinazoline substitués et procédés d'utilisation
KR102444509B1 (ko) 2016-05-18 2022-09-19 미라티 테라퓨틱스, 인크. Kras g12c 억제제
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018064510A1 (fr) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibiteurs de protéines mutantes kras g12c
EP3523289A1 (fr) 2016-10-07 2019-08-14 Araxes Pharma LLC Composés hétérocycliques en tant qu'inhibiteurs de ras et leurs procédés d'utilisation
US11104955B2 (en) 2016-12-30 2021-08-31 Children's Medical Center Corporation MAP2K1 (MEK1) as a therapeutic target for arteriovenous malformations and associated disorders
EP3573954A1 (fr) 2017-01-26 2019-12-04 Araxes Pharma LLC Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation
WO2018140513A1 (fr) 2017-01-26 2018-08-02 Araxes Pharma Llc Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (fr) 2017-01-26 2018-08-02 Araxes Pharma Llc Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
CN110869357A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 化合物及其用于治疗癌症的使用方法
WO2018218069A1 (fr) 2017-05-25 2018-11-29 Araxes Pharma Llc Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
LT3710439T (lt) 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
WO2019217307A1 (fr) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
JP2021527648A (ja) 2018-06-15 2021-10-14 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の低減
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
EP3849535A4 (fr) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Polythérapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
EP3849537B1 (fr) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Polythérapies
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (fr) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. Inhibiteurs de kras g12c
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021061749A1 (fr) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Polythérapies
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
WO2021222138A1 (fr) * 2020-04-27 2021-11-04 Development Center For Biotechnology Composés pour la dégradation de la protéine ras mutante
EP4210833A4 (fr) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. Formes cristallines d'un inhibiteur de kras g12c
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (fr) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Inhibiteurs pan-kras de tétrahydropyridopyrimidine
WO2023150639A2 (fr) * 2022-02-04 2023-08-10 The Board Of Trustees Of The Leland Stanford Junior University Modulateurs à petites molécules d'enzymes gtpase et leurs utilisations
TW202404643A (zh) 2022-04-20 2024-02-01 大陸商同宜醫藥（蘇州）有限公司 化合物及用途
WO2025148858A1 (fr) * 2024-01-08 2025-07-17 应世生物科技(南京)有限公司 Inhibiteur de fak et inhibiteur pan-ras

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169788B2 (en) * 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
JP5460054B2 (ja) * 2005-11-23 2014-04-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法
AU2012296346A1 (en) * 2011-08-18 2014-04-03 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
EP2836482B1 (fr) * 2012-04-10 2019-12-25 The Regents of The University of California Compositions et méthodes pour le traitement du cancer
EP2671575A1 (fr) * 2012-06-04 2013-12-11 Universität Regensburg Inhibiteurs de RAS
WO2015074123A1 (fr) * 2013-11-25 2015-05-28 Novogen ltd Indoles fonctionnalisés et substitués utilisés en tant qu'agents anti-cancéreux
WO2017096045A1 (fr) * 2015-12-02 2017-06-08 Kyras Therapeutics, Inc. Composés de liaison ras multivalents

Also Published As

Publication number Publication date
EP3148981A4 (fr) 2017-11-08
CA2950581A1 (fr) 2015-12-03
WO2015184349A2 (fr) 2015-12-03
EP3148981A2 (fr) 2017-04-05
WO2015184349A3 (fr) 2016-01-21
US20160229836A1 (en) 2016-08-11
US9926293B2 (en) 2018-03-27

Similar Documents

Publication Publication Date Title
MA40074A (fr) Composés liant ras multivalents
MX2018016344A (es) Miembros de union lag-3.
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
EA202091540A1 (ru) Антитела к lilrb2
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
NZ754051A (en) Novel antibodies and uses thereof
MX2018006477A (es) Anticuerpos y metodos de uso de estos.
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
CL2017001154A1 (es) Moléculas de unión específicas para cd73 y usos de las mismas
PH12016501366A1 (en) Novel anti-baff antibodies
MY184895A (en) Antibody constructs for dll3 and cd3
PH12018500216B1 (en) Antibody constructs for cd70 and cd3
NZ738979A (en) Pd-1 antibodies
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
PH12018500156A1 (en) Antibody constructs for egfrviii and cd3
WO2017035430A3 (fr) Anticorps anti-alk et leurs procédés d'utilisation
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
WO2019089753A3 (fr) Anticorps cd137 et antagonistes pd-1 et leurs utilisations
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
MX2018011244A (es) Anticuerpos monoclonales neutralizantes para il-25 y usos de estos.